SCHEMBL7746677

SCHEMBL7746677

O=C(c1cc(Cl)nc2ccccc12)N1CCOCC1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.71
TSHR P16473 2/20 0.71
LMNA P02545 1/20 0.71
KDM4E B2RXH2 3/20 0.67
SMN1; SMN2 Q16637 1/20 0.65
USP2 O75604 1/20 0.64
TP53 P04637 1/20 0.64
POLB P06746 1/20 0.64
HPGD P15428 1/20 0.64
HSD17B10 Q99714 1/20 0.64
MOK Q9UQ07 1/20 0.58
PLAUR Q03405 2/20 0.55
PKM P14618 1/20 0.54
CNR1 P21554 1/20 0.53
CYP3A4 P08684 2/20 0.53
CYP2C9 P11712 2/20 0.53
CYP2C19 P33261 2/20 0.53
CYP1A2 P05177 1/20 0.52
HTT P42858 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26107773 0.88 SMN1; SMN2 (0.69) KDM4ESMN1; SMN2POLBMOKCYP2C9
SCHEMBL17433822 0.84 ALDH1A1 (0.57) ALDH1A1TSHRLMNAKDM4ESMN1; SMN2
SCHEMBL31429048 0.84 ALDH1A1 (0.71) ALDH1A1TSHRLMNAKDM4EUSP2
SCHEMBL15237515 0.84 ALDH1A1 (0.71) ALDH1A1TSHRLMNAKDM4ESMN1; SMN2
SCHEMBL10760683 0.83 ALDH1A1 (1.00) ALDH1A1TSHRLMNAKDM4ESMN1; SMN2
SCHEMBL31428429 0.82 ALDH1A1 (0.68) ALDH1A1TSHRLMNAKDM4ESMN1; SMN2
SCHEMBL13236255 0.81 ALDH1A1 (0.70) ALDH1A1TSHRLMNAKDM4ESMN1; SMN2
SCHEMBL13210068 0.81 ALDH1A1 (0.67) ALDH1A1TSHRLMNAKDM4EUSP2
SCHEMBL13209734 0.79 ALDH1A1 (0.67) ALDH1A1TSHRLMNAKDM4ESMN1; SMN2
SCHEMBL13209769 0.79 ALDH1A1 (0.67) ALDH1A1TSHRLMNAKDM4EUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11192859-B2 Quinoline compounds as modulators of RAGE activity and uses thereof UNIV NEW YORK (US) 2021-12-07 US disclosed
US-20190194136-A1 QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF UNIV NEW YORK (US) 2019-06-27 US disclosed
WO-2017184547-A1 QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF NEW YORK UNIVERSITY (US) 2017-10-26 WO disclosed
US-9040706-B2 Pyrrolidine inhibitors of IAP GENENTECH, INC. (US) 2015-05-26 US disclosed
US-9040706-B2 Pyrrolidine inhibitors of IAP GENENTECH, INC. (US) 2015-05-26 US disclosed
US-20140080805-A1 PYRROLIDINE INHIBITORS OF IAP GENENTECH, INC. (US) 2014-03-20 US disclosed
US-20140080805-A1 PYRROLIDINE INHIBITORS OF IAP GENENTECH, INC. (US) 2014-03-20 US disclosed
EP-1836201-B2 PYRROLIDINE INHIBITORS OF IAP GENENTECH INC (US) 2013-09-04 EP disclosed
EP-1836201-B1 PYRROLIDINE INHIBITORS OF IAP GENENTECH INC (US) 2010-08-11 EP disclosed
US-20090318409-A1 PYRROLIDINE INHIBITORS OF IAP GENENTECH, INC. (US) 2009-12-24 US disclosed
US-20090318409-A1 PYRROLIDINE INHIBITORS OF IAP GENENTECH, INC. (US) 2009-12-24 US disclosed
US-20090176822-A1 PYRROLIDINE INHIBITORS OF IAP GENENTECH, INC. (US) 2009-07-09 US disclosed
US-20090176822-A1 PYRROLIDINE INHIBITORS OF IAP GENENTECH, INC. (US) 2009-07-09 US disclosed
US-6214996-B1 SHOWING EXCELLENT BRONCHIOCONSTRICTION INHIBITORY ACTIVITY,USEFUL IN THE PROPHYLAXIS OR TREATNEBT OF ASTHMA TANABE SEIYAKU CO., LTD. (JP) 2001-04-10 US disclosed
US-6005106-A BRONCHOCONSTRICTOR AGENTS USEFUL IN THE TREATMENT OF ASTHMA TANABE SEIYAKU CO., LTD. (JP) 1999-12-21 US disclosed
US-5969140-A AMINOPYRIDINE DERIVATIVES OF NAPHTHALENE FOR TREATMENT OF ASTHMA AND BRONCHOCONSTRICTOR INHIBITORS TANABE SEIYAKU CO., LTD. (JP) 1999-10-19 US disclosed
EP-0748805-B1 Naphthalene derivatives, process for the preparation thereof, and intermediates therefor, and pharmaceutical compositions comprising them TANABE SEIYAKU CO (JP) 1998-04-08 EP disclosed
EP-0748805-A1 Naphthalene derivatives, process for the preparation thereof, and intermediates therefor, and pharmaceutical compositions comprising them TANABE SEIYAKU CO., LTD. (JP) 1996-12-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176822-A1 PYRROLIDINE INHIBITORS OF IAP BIRC5, XIAP, BIRC2 ALDH1A1 4197/4885TSHR 3205/4885LMNA 2663/4885
US-20190194136-A1 QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF AGER, HMGB1, GPR119 ALDH1A1 1885/4885TSHR 2426/4885LMNA 793/4885
US-20140080805-A1 PYRROLIDINE INHIBITORS OF IAP BIRC5, XIAP, BIRC2 ALDH1A1 4197/4885TSHR 3205/4885LMNA 2663/4885
US-11192859-B2 Quinoline compounds as modulators of RAGE activity and uses thereof AGER, HMGB1, GPR119 ALDH1A1 1885/4885TSHR 2426/4885LMNA 793/4885
US-20090318409-A1 PYRROLIDINE INHIBITORS OF IAP BIRC5, XIAP, BIRC2 ALDH1A1 4197/4885TSHR 3205/4885LMNA 2663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.